Evaluation of angiopoietin-2 level in patients with multiple myeloma at presentation and in remission state
BACKGROUND: Angiopoietin-2 (ANG-2) regulates angiogenesis and enhances the formation of new vessels in tumors by boosting the effect of vascular endothelial growth factor as part of dynamic neovascularization. ANG-2 is a marker of disease progression and therapy response in multiple myeloma (MM). O...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Iraqi Journal of Hematology |
| Subjects: | |
| Online Access: | http://www.ijhonline.org/article.asp?issn=2072-8069;year=2023;volume=12;issue=1;spage=8;epage=12;aulast=Salih |
| _version_ | 1797774127502721024 |
|---|---|
| author | Zahraa Mudher M Salih Haithem Ahmed Al-Rubaie |
| author_facet | Zahraa Mudher M Salih Haithem Ahmed Al-Rubaie |
| author_sort | Zahraa Mudher M Salih |
| collection | DOAJ |
| description | BACKGROUND: Angiopoietin-2 (ANG-2) regulates angiogenesis and enhances the formation of new vessels in tumors by boosting the effect of vascular endothelial growth factor as part of dynamic neovascularization. ANG-2 is a marker of disease progression and therapy response in multiple myeloma (MM).
OBJECTIVES: The study aimed to assess the level of ANG-2 in MM patients at diagnosis and in remission state and elaborate on its correlation with interleukin-6 (IL-6) and beta-2 microglobulin (B2M) levels.
PATIENTS, MATERIALS, AND METHODS: Sixty MM patients; 20 newly diagnosed (ND), and 40 patients in remission were included. Twenty healthy individuals were included as a control group. Plasma levels of ANG-2, B2M, and IL-6 were tested by enzyme-linked immunosorbent assay.
RESULTS: There are significant statistical differences between ND patients and those in remission in hemoglobin, neutrophil count, blood urea, serum creatinine, glomerular filtration rate, B2M, IL6, and ANG-2 (P = 0.001, 0.033, 0.005, 0.001, 0.001, 0.001, 0.004, and 0.001, respectively). ANG-2 showed significant positive correlations with B2M (P = 0.001) and IL-6 (P = 0.012).
CONCLUSION: The low ANG-2 level in the remission group with an insignificant difference from that in the control group with a high level in the untreated patients renders it a useful indicator for treatment response follow-up in MM. The positive correlation of ANG-2 with B2M and IL-6 reflects the active angiogenesis with a high tumor burden and disease progression. |
| first_indexed | 2024-03-12T22:15:30Z |
| format | Article |
| id | doaj.art-0307b3092c374d9fa9f09bc24000a238 |
| institution | Directory Open Access Journal |
| issn | 2072-8069 |
| language | English |
| last_indexed | 2024-03-12T22:15:30Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Iraqi Journal of Hematology |
| spelling | doaj.art-0307b3092c374d9fa9f09bc24000a2382023-07-23T11:17:34ZengWolters Kluwer Medknow PublicationsIraqi Journal of Hematology2072-80692023-01-0112181210.4103/ijh.ijh_23_23Evaluation of angiopoietin-2 level in patients with multiple myeloma at presentation and in remission stateZahraa Mudher M SalihHaithem Ahmed Al-RubaieBACKGROUND: Angiopoietin-2 (ANG-2) regulates angiogenesis and enhances the formation of new vessels in tumors by boosting the effect of vascular endothelial growth factor as part of dynamic neovascularization. ANG-2 is a marker of disease progression and therapy response in multiple myeloma (MM). OBJECTIVES: The study aimed to assess the level of ANG-2 in MM patients at diagnosis and in remission state and elaborate on its correlation with interleukin-6 (IL-6) and beta-2 microglobulin (B2M) levels. PATIENTS, MATERIALS, AND METHODS: Sixty MM patients; 20 newly diagnosed (ND), and 40 patients in remission were included. Twenty healthy individuals were included as a control group. Plasma levels of ANG-2, B2M, and IL-6 were tested by enzyme-linked immunosorbent assay. RESULTS: There are significant statistical differences between ND patients and those in remission in hemoglobin, neutrophil count, blood urea, serum creatinine, glomerular filtration rate, B2M, IL6, and ANG-2 (P = 0.001, 0.033, 0.005, 0.001, 0.001, 0.001, 0.004, and 0.001, respectively). ANG-2 showed significant positive correlations with B2M (P = 0.001) and IL-6 (P = 0.012). CONCLUSION: The low ANG-2 level in the remission group with an insignificant difference from that in the control group with a high level in the untreated patients renders it a useful indicator for treatment response follow-up in MM. The positive correlation of ANG-2 with B2M and IL-6 reflects the active angiogenesis with a high tumor burden and disease progression.http://www.ijhonline.org/article.asp?issn=2072-8069;year=2023;volume=12;issue=1;spage=8;epage=12;aulast=Salihangiopoietin-2complete remissionmultiple myeloma |
| spellingShingle | Zahraa Mudher M Salih Haithem Ahmed Al-Rubaie Evaluation of angiopoietin-2 level in patients with multiple myeloma at presentation and in remission state Iraqi Journal of Hematology angiopoietin-2 complete remission multiple myeloma |
| title | Evaluation of angiopoietin-2 level in patients with multiple myeloma at presentation and in remission state |
| title_full | Evaluation of angiopoietin-2 level in patients with multiple myeloma at presentation and in remission state |
| title_fullStr | Evaluation of angiopoietin-2 level in patients with multiple myeloma at presentation and in remission state |
| title_full_unstemmed | Evaluation of angiopoietin-2 level in patients with multiple myeloma at presentation and in remission state |
| title_short | Evaluation of angiopoietin-2 level in patients with multiple myeloma at presentation and in remission state |
| title_sort | evaluation of angiopoietin 2 level in patients with multiple myeloma at presentation and in remission state |
| topic | angiopoietin-2 complete remission multiple myeloma |
| url | http://www.ijhonline.org/article.asp?issn=2072-8069;year=2023;volume=12;issue=1;spage=8;epage=12;aulast=Salih |
| work_keys_str_mv | AT zahraamudhermsalih evaluationofangiopoietin2levelinpatientswithmultiplemyelomaatpresentationandinremissionstate AT haithemahmedalrubaie evaluationofangiopoietin2levelinpatientswithmultiplemyelomaatpresentationandinremissionstate |